Literature DB >> 10563835

New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6, 7-dihydroxytetrahydroisoquinoline.

A Napolitano1, A Pezzella, G Prota.   

Abstract

Aerial oxidation of dopamine at concentrations as low as 50 microM in the presence of ferrous ions in phosphate buffer (pH 7.4) led in the early stages (6-8 h) to the formation of the quinone of the neurotoxin 6-hydroxydopamine, 2, followed (24 h) by a complex product pattern comprising main components norepinephrine (5), 3, 4-dihydroxybenzaldehyde (4), and the neurotoxic alkaloid 6, 7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (3). Product formation required the assistance of metal ions such as Mn(II), Zn(II), and iron, in either the ferrous or ferric form. Product yields were shown to vary linearly with iron and dopamine concentration in the early phases of the reaction (2 h). Biologically relevant antioxidants, like glutathione and ascorbate, and metal chelators, e. g., 2,2'-bipyridyl, inhibited dopamine conversion to products 2-5, but not substrate consumption, while hydroxyl radical scavengers such as DMSO and mannitol did not alter the course of the reaction. On the contrary, mannitol increased product yields, an effect seen for other monosaccharides. Catalase exhibited a significant inhibitory effect particularly on the formation of 3 and 4. By using (18)O(2), evidence was obtained for incorporation of the label into the carbonyl oxygen of 4, but not into the hydroxyl group of 5. On the basis of these and other results, a complete mechanistic picture of the oxidation is drawn involving conversion of dopamine to the corresponding o-quinone and its quinonemethide tautomer with concomitant reduction of O(2) to H(2)O(2). Nucleophilic attack by H(2)O to the quinonemethide gives rise to 5, while H(2)O(2) addition leads to benzaldehyde 4 via a beta-aminohydroperoxide intermediate. This latter reaction path also gives formaldehyde which yields the isoquinoline 3 by Pictet-Spengler condensation with dopamine. The quinone 2 results from H(2)O(2) attack at the 6-position of dopamine o-quinone in agreement with previous studies. These results provide an insight into new routes of nonenzymatic conversion of dopamine to its metabolite norepinephrine and neurotoxic species which may become operative under conditions relevant to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563835     DOI: 10.1021/tx990079p

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  11 in total

Review 1.  The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications.

Authors:  George Perry; Lawrence M Sayre; Craig S Atwood; Rudolph J Castellani; Adam D Cash; Catherine A Rottkamp; Mark A Smith
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease.

Authors:  Dianlu Jiang; Shuyun Shi; Lin Zhang; Lin Liu; Bingrong Ding; Bingqing Zhao; Gargey Yagnik; Feimeng Zhou
Journal:  ACS Chem Neurosci       Date:  2013-07-17       Impact factor: 4.418

3.  Separation of intermediates of iron-catalyzed dopamine oxidation reactions using reversed-phase ion-pairing chromatography coupled in tandem with UV-visible and ESI-MS detections.

Authors:  Lin Zhang; Gargey Yagnik; Dianlu Jiang; Shuyun Shi; Peter Chang; Feimeng Zhou
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-10-29       Impact factor: 3.205

4.  Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.

Authors:  Camila Mouhape; Gustavo Costa; Margot Ferreira; Juan Andrés Abin-Carriquiry; Federico Dajas; Giselle Prunell
Journal:  Neurotox Res       Date:  2018-07-13       Impact factor: 3.911

5.  Why are neurotransmitters neurotoxic? An evolutionary perspective.

Authors:  Keith D Harris; Meital Weiss; Amotz Zahavi
Journal:  F1000Res       Date:  2014-07-30

6.  Neuroprotective effects of herbal ethanol extracts from Gynostemma pentaphyllum in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Authors:  Hyun Sook Choi; Mi Sook Park; Seung Hwan Kim; Bang Yeon Hwang; Chong Kil Lee; Myung Koo Lee
Journal:  Molecules       Date:  2010-04-16       Impact factor: 4.411

Review 7.  Potential of Naturally Derived Alkaloids as Multi-Targeted Therapeutic Agents for Neurodegenerative Diseases.

Authors:  Yew Rong Kong; Kai Ching Tay; Yi Xiang Su; Choon Kwang Wong; Wen Nee Tan; Kooi Yeong Khaw
Journal:  Molecules       Date:  2021-01-30       Impact factor: 4.411

8.  The Cyclic Nitroxide TEMPOL Ameliorates Oxidative Stress but Not Inflammation in a Cell Model of Parkinson's Disease.

Authors:  Alexander Leathem; Martin Simone; Joanne M Dennis; Paul K Witting
Journal:  Antioxidants (Basel)       Date:  2022-01-28

9.  Complexity of dopamine metabolism.

Authors:  Johannes Meiser; Daniel Weindl; Karsten Hiller
Journal:  Cell Commun Signal       Date:  2013-05-17       Impact factor: 5.712

10.  Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines.

Authors:  Yingying Sun; A Ninh Pham; T David Waite
Journal:  J Neurochem       Date:  2016-05-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.